Abstract: Antibodies that protect against respiratory viral infections including human parainfluenza viruses (HPIV), respiratory syncytial virus (RSV), and human metapneumovirus (HMPV) are described. Certain antibodies disclosed herein neutralize more than one virus (e.g., RSV and HMPV). The binding fragments of the antibodies can be engineered into numerous formats including those that provide simultaneous protection against multiple viruses.
Type:
Application
Filed:
February 25, 2022
Publication date:
May 9, 2024
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Justin J. Taylor, Jim Boonyaratanakornkit
Abstract: The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.
Type:
Grant
Filed:
November 8, 2018
Date of Patent:
April 30, 2024
Assignees:
Fred Hutchinson Cancer Center, Massachusetts Institute of Technology
Inventors:
Damian J. Green, Yukang Lin, Oliver W. Press, Alice Tzeng, Karl Dane Wittrup
Abstract: Antibodies that bind the tumor (T) antigen of the Merkel cell polyomavirus are disclosed. The antibodies can be use used in cell-based immunotherapies, antibody-based therapies, diagnostics, and detection assays, among other uses.
Type:
Application
Filed:
October 22, 2023
Publication date:
April 25, 2024
Applicants:
Fred Hutchinson Cancer Center, University of Washington
Inventors:
Justin J. Taylor, Denise Galloway, Paul Nghiem, David Koelle, Haroldo Rodriguez, Joseph Carter
Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.
Type:
Application
Filed:
June 29, 2023
Publication date:
April 18, 2024
Applicants:
Seattle Children's Hospital (d/b/a Seattle Children's Research Institute), Fred Hutchinson Cancer Center
Inventors:
Andrew Scharenberg, Kyle Jacoby, Hans-Peter Kiem, David J. Rawlings, Christopher Lux, Sowmya Pattabhi, Olivier M. Humbert
Abstract: Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.
Type:
Application
Filed:
July 11, 2023
Publication date:
March 21, 2024
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Jason Price, Colin E. Correnti, James M. Olson
Abstract: Chimeric antigen receptors (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALY(SEQ ID NO: 94)/HLA-A2 are disclosed. The CAR can be used to treat PRAME/HLA-A2 expressing cancers such as the t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia (AML).
Type:
Application
Filed:
August 23, 2023
Publication date:
March 21, 2024
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Soheil Meshinchi, Danielle Kirkey, Anisha Loeb, Quy H. Le
Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.
Type:
Application
Filed:
June 12, 2023
Publication date:
March 21, 2024
Applicants:
Fred Hutchinson Cancer Center, Memorial Sloan-Kettering Cancer Center
Inventors:
Jarrod Dudakov, Marcel van den Brink, Enrico Velardi, Hans-Peter Kiem, Stefan Radtke, Scott James
Abstract: Anti-Epstein Barr Virus (EBV) vaccines are described herein. The EBV vaccine antigens are linked to a multimerization domain, for example, presented on a circular tandem repeat protein (cTRP) scaffold or linked to a C4b multimerization domain. The vaccines can be used to treat and/or reduce the risk of EBV infection and to treat and/or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.
Type:
Application
Filed:
August 29, 2023
Publication date:
March 21, 2024
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Jason Price, James M. Olson, Andrew McGuire, Barry L. Stoddard
Abstract: Delta-like non-canonical Notch ligand 1 (DLK1) inhibitors are disclosed. The DLK1 inhibitors can be used to treat cancers such as myelodysplastic syndrome (MDS), and cancers of the liver, breast, brain, pancreas, colon, lung, kidney, ovary, testes, and/or adrenal gland, among other uses described herein.
Type:
Application
Filed:
August 25, 2023
Publication date:
March 21, 2024
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Irwin D. Bernstein, Suzanne Furuyama, Kristen Johnson
Abstract: The present disclosure relates to anti-ROR1 binding proteins, including those that bind to a ROR1 or portion thereof such as an intracellular C terminal portion of a ROR1 protein, and the use of such binding proteins in immunohistochemical and diagnostic methods. Related kits and methods of using the binding proteins are also provided, as are methods of treatment of subjects having diseases or conditions determined to be candidates for such treatments by the binding proteins or methods of this disclosure.
Type:
Grant
Filed:
January 25, 2021
Date of Patent:
March 19, 2024
Assignee:
Fred Hutchinson Cancer Center
Inventors:
Ashwini Balakrishnan, Benjamin G. Hoffstrom, Julie Randolph-Habecker, Stanley R. Riddell
Abstract: Mutated and/or truncated malarial circumsporozoite proteins (CSP) and associated nucleic acids that are more stable and highly expressed in mammalian cells are described. The mutated and/or truncated CSP and associated nucleic acids can be expressed to produce malaria vaccine antigens.
Abstract: A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells.
Type:
Grant
Filed:
June 29, 2018
Date of Patent:
February 20, 2024
Assignee:
Fred Hutchinson Cancer Center
Inventors:
Harlan S. Robins, Edus H. Warren, Christopher Scott Carlson
Abstract: Systems and methods to link CD40 signaling to antigen binding, independently of CD40 ligand binding are described. The systems and methods include fusion proteins including an extracellular antigen binding domain linked to an intracellular CD40 signaling domain.
Type:
Application
Filed:
February 8, 2022
Publication date:
February 15, 2024
Applicants:
Fred Hutchinson Cancer Center, University of Washington
Inventors:
Justin J. Taylor, Laila Shehata, Marti Tooley
Abstract: Mutated and/or truncated malarial circumsporozoite proteins (CSP) and associated nucleic acids that are more stable and highly expressed in mammalian cells are described. The mutated and/or truncated CSP and associated nucleic acids can be expressed to produce malaria vaccine antigens.
Abstract: Hematopoietic stem/progenitor cells (HSPC) and/or non-T effector cells are genetically modified to express (i) an extracellular component including a ligand binding domain that binds a cellular marker preferentially expressed on an unwanted cell; and (ii) an intracellular component comprising an effector domain. Among other uses, the modified cells can be administered to patients to target unwanted cancer cells without the need for immunological matching before administration.
Type:
Application
Filed:
November 28, 2022
Publication date:
February 8, 2024
Applicants:
Fred Hutchinson Cancer Center, Seattle Children's Hospital d/b/a Seattle Children's Research Institute
Inventors:
Colleen Delaney, Michael Jensen, Rebecca Gardner
Abstract: Provided herein are methods to reduce tumor cell proliferation in a cancer patient by administering an antibody that binds angiopoietin-like 7, wherein administering the angiopoietin-like 7 antibody can reduce necrosis formation, metastasis formation, and circulating tumor cells.
Type:
Application
Filed:
August 3, 2023
Publication date:
February 8, 2024
Applicant:
Fred Hutchinson Cancer Center
Inventors:
Kevin Cheung, Ami Yamamoto, Brad Krajina, Yin Huang
Abstract: Methods to create barcoded influenza viruses without disrupting the function of the viral proteins and the proper packaging of the viral genome segments are described. The barcoded influenza viruses can be used within deep mutational scanning libraries to map influenza resistance mutations to therapeutic treatments. The libraries can also be used to predict influenza strains that may become resistant to therapeutic treatments and/or more easily evolve to infect new species. The libraries include features that allow efficient collection and assessment of informative data, obviating bottlenecks of previous approaches.
Type:
Application
Filed:
October 19, 2023
Publication date:
February 8, 2024
Applicants:
Fred Hutchinson Cancer Center, University of Washington
Inventors:
Jesse Bloom, Allison Greaney, Andrea Loes, Adam S. Dingens
Abstract: The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.
Abstract: Implantable scaffolds that treat solid tumors and escape variants and that provide effective vaccinations against cancer recurrence are described. The scaffolds include genetically-reprogrammed lymphocytes and a lymphocyte-activating moiety.